The Need for Faster Insulin: Problem Solved?

Journal of Diabetes Science and Technology

Volumn 11, Issue 1, 2017, Pages 157-159

  Muchmore, Douglas B ^a  

^a Kinexum   (United States)

Author keywords

Afrezza; insulin pharmacokinetics; pulmonary insulin; ultrafast insulin

Indexed keywords

INSULIN LISPRO; RECOMBINANT HUMAN INSULIN; ANTIDIABETIC AGENT; INSULIN;

CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; HORMONE SUBSTITUTION; HUMAN; HYPOGLYCEMIA; INHALATION; INSULIN TREATMENT; LUNG CANCER; PHARMACODYNAMICS; REVIEW; RISK REDUCTION; SIDE EFFECT; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 85009257883     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296816677577     Document Type: Review

References (12)

1. Home PD., Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes? Diabetes Obes Metab. 2015; 17 (11): 1011-1020.
2. Cobry E, McFann Messer L, et al. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther. 2010; 12: 173-177.
3. Heinemann L, Muchmore DB., Ultra-fast insulins: state of the art. J Diabetes Sci Technol. 2012; 6: 728-742.
4. Heinemann L, Baughman R, Boss A, Hompesch M,. Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin. [published online ahead of print July 3, 2016]. J Diabetes Sci Technol. pii: 1932296816658055.
5. Kruszynska YT, Home PD, Hanning I, Alberti KGMM,. Basal and 24-h C-peptide and insulin secretion rate in normal man. Diabetologia. 1987; 30: 16-21.
6. Bode BW, McGill JB, Lorber DL, et al. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015; 38: 2266-2273.
7. Boss AH, Petrucci R, Lorber D., Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin. J Diabetes Sci Technol. 2012; 6: 773-779.
8. DeFronzo R, Ferrannini E, Hendler R, et al. Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. Diabetes. 1983; 32: 35-45.
9. Potocka E, Hovorka R, Baughman RA, et al. AFRESA suppresses endogenous glucose production earlier than a rapid-acting analog (lispro) and inhaled exubera. Diabetes. 2009; 58 (suppl 1):abstract 232-OR.
10. Cassidy JP, Amin N, Marino M, et al. Insulin lung deposition and clearance following Technosphere insulin inhalation powder administration. Pharm Res. 2011; 28: 2157-2164.
11. Meeting transcript from FDA Endocrinologic and Metabolic Advisory Committee, 1, 2014, recorded by Capital Reporting Company. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm400452.pdf. Accessed October 5, 2016.
12. FDA staff presentation slides from FDA Endocrinologic and Metabolic Advisory Committee. 1, 2014. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm392917.pdf. Accessed October 5, 2016.